Comparison of the additive effects of nipradilol and carteolol to latanoprost in open-angle glaucoma

• Published in: Japanese journal of ophthalmology Vol. 50; no. 1; pp. 33 - 37
• Main Authors: Haneda, Mai, Shirato, Shiroaki, Maruyama, Katsuhiko, Ohno, Yuko
• Format: Journal Article
• Language: English
• Published: Japan Springer Nature B.V 01.01.2006
• Subjects: Antihypertensive Agents - administration & dosage; Antihypertensive Agents - adverse effects; Antihypertensive Agents - therapeutic use; Carteolol - administration & dosage; Carteolol - adverse effects; Carteolol - therapeutic use; Cross-Over Studies; Drug Therapy, Combination; Female; Glaucoma; Glaucoma, Open-Angle - drug therapy; Humans; Intraocular Pressure - drug effects; Male; Middle Aged; Propanolamines - administration & dosage; Propanolamines - adverse effects; Propanolamines - therapeutic use; Prostaglandins F, Synthetic - administration & dosage; Prostaglandins F, Synthetic - adverse effects; Prostaglandins F, Synthetic - therapeutic use; Tonometry, Ocular
• ISSN: 0021-5155; 1613-2246
• DOI: 10.1007/s10384-005-0256-2

To compare the effects of nipradilol and carteolol on intraocular pressure (IOP) when added to latanoprost treatment for glaucoma patients. Fifty patients with primary open-angle glaucoma were treated with latanoprost 0.005% once daily for 3 months. Then they were assigned to one of two groups randomly. One group received nipradilol 0.25% twice daily (nipradilol preceding group; n = 25), and the other carteolol hydrochloride 2% twice daily (carteolol preceding group; n = 25), for 3 months in addition to latanoprost. Then, nipradilol and carteolol were switched, and the subjects were treated for 3 more months. One eye was selected randomly for analysis. In the nipradilol preceding group, IOP was 21.4 +/- 2.3 mmHg (mean +/- SD) at baseline, and 16.8 +/- 1.9 mmHg at the end of latanoprost monotherapy (P < 0.01). The addition of nipradilol decreased IOP to 15.8 +/- 1.7 mmHg, and the change to carteolol, to 15.3 +/- 2.0 mmHg. In the carteolol preceding group, IOP was 21.2 +/- 2.0 mmHg at baseline, and 17.0 +/- 2.1 mmHg at the end of latanoprost monotherapy (P < 0.01). The addition of carteolol decreased IOP to 15.4 +/- 1.8 mmHg, and the change to nipradilol, to 16.3 +/- 1.9 mmHg. Additional IOP reduction was greater with carteolol than with nipradilol (cross-over analysis of variance; P = 0.0005). Both nipradilol and carteolol have additive effects when used in combination with latanoprost. Carteolol, however, may have a more potent effect than nipradilol.